Navigation Links
StageBio and Alizée Pathology join forces to meet the growing demand for high-quality histopathology and medical device services in the preclinical services market
Date:11/9/2019

StageBio has merged with Alizée Pathology to form the leading provider of specialized histology, pathology, biomarker development, and archiving services for the biopharmaceutical, medical device and contract research industries. StageBio was recently created by the mergers of Histo-Scientific Research Laboratories (HSRL), Vet Path Services (VPS) and Tox Path Specialists (TPS), and now includes Alizée Pathology. StageBio is a portfolio company of Ampersand Capital Partners.

“Dr. Serge Rousselle, Dr. Joan Wicks and the Alizée staff bring unique histopathology capabilities to StageBio. These services enable us to offer the industry an even broader range of highly specialized histopathology and imaging services,” said Mr. Thomas Galati, StageBio CEO. “We have successfully merged HSRL, VPS and TPS, and are excited to add Alizée’s expertise to our growing list of offerings.”

Dr. Serge Rousselle, Co-Founder of Alizée Pathology, commented, “StageBio and Alizée have been working closely for years, and this union is a natural evolution of that relationship. The broad client base and services at StageBio, combined with the specialty expertise at Alizée, are a winning combination for our clients.” The merger adds laboratory space in Thurmont and Cumberland MD, as well as staff with experience in specialty medical devices and biomarkers/biologics that will complement the StageBio team based in Virginia, Massachusetts, Ohio, and Maryland. The combined company now employs 28 board-certified (ACVP) Veterinary Pathologists with a total employee base of over 150.

About StageBio

StageBio is the leading provider of GLP-compliant research and preclinical histology, pathology and specimen archiving services for the biopharmaceutical, medical device and contract research industries. We provide our customers with a fully integrated breadth of histopathology services, including tissue analysis, efficacy determination for new compounds and devices, toxicological evaluation of products subject to FDA approval, detailed pathology reporting for GLP studies, medical device pathology and immunohistochemistry. We operate numerous state-of-the-art sites in Virginia, Massachusetts, Ohio, and Maryland, with substantial continued investment in our facility and technology infrastructures to meet the growing demand for high-quality histopathology services. We are ideally positioned to deliver on our unified commitment to quality, scientific integrity and customer service excellence. Additional information about StageBio is available at http://www.stagebio.com.

About Alizée Pathology

Founded in 2010, Alizée Pathology is one of the leading preclinical medical device laboratories in North America. Founded and led by Drs. Serge Rousselle and Joan Wicks, Alizée provides GLP-compliant services in support of the development of novel devices and therapeutics. Alizée’s team is comprised of ACVP boarded Pathologists, PhDs, MDs and highly trained scientists who are focused on delivering clear, reproducible, and contextual results. Alizée services the following areas of preclinical medicine and science: bone repair, interventional medicine, oncology, inflammatory diseases, immunotherapy, regenerative medicine, surgical tools, pharmaceuticals and tissue phenotyping. Included among its staff are 4 board-certified (ACVP) Veterinary Pathologists, more than 20 highly trained histology technicians and scientists and a dedicated Quality Assurance (QA) unit. The entire team is committed to the highest quality work and excellent customer service. Additional information about Alizée is available at http://www.alizeepathology.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics and Viracor-IBT Laboratories. Additional information about Ampersand is available at http://www.ampersandcapital.com.

Read the full story at https://www.prweb.com/releases/stagebio_and_alizee_pathology_join_forces_to_meet_the_growing_demand_for_high_quality_histopathology_and_medical_device_services_in_the_preclinical_services_market/prweb16710033.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Visikol Releases Open Source 3Screen™ Python Library for Training Convolutional Neural Networks for Use in Digital Pathology
2. Scientists discover a new role for estrogen in the pathology of breast cancer
3. Scientists provide insight into the pathology of Sanfilippo A syndrome
4. 1 species, 2 outcomes: Team seeks source of body louse pathology
5. The Association for Molecular Pathology announces highlights of Phoenix meeting
6. Resveratrol, found in red wine, worsens MS-like symptoms and neuropathology in mice
7. From eons to seconds, proteins exploit the same forces
8. Illinois researchers combine weak chemical forces to strengthen novel imaging technology
9. Mechanical forces driving breast cancer lead to key molecular discovery
10. Europe is joining forces against neglected parasitic diseases
11. Crop-infecting virus forces aphids to spread disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. ... the global economic downturn will only increase price pressures overall for the industry. The ... value from every product launch is critical. However, history shows that only a third ...
(Date:7/4/2020)... ... 2020 , ... Aesthetics Biomedical (ABM), a leading aesthetics product ... only the products and treatments developed, but also the dedicated team behind the ... brands built by ABM have received several honors already for 2020, each of ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the ... clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and ... Known as MediVet Biologics since its formation in 2016, the company is relaunching itself ... will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. has introduced ... configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar Transmitter ... in a push-pull configuration; yielding fast fall time for a capacitive load. These ...
(Date:7/31/2020)... TORONTO (PRWEB) , ... July 29, 2020 , ... eSource ... and inefficiencies. This webinar will cover the history of eSource, the reasons it did ... From EMR/EHR to wearables, to site source, the industry is moving towards capturing data ...
(Date:7/22/2020)... ... , ... Join experts from Reed Tech , Gary Saner, Sr. Manager, ... hour live webinar on Thursday, August 13, 2020 at 11am EDT (4pm ... devices. Specifically, for medical devices, the NMPA has departments dealing with medical device registration ...
Breaking Biology Technology: